UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
AUGUST 13, 2010
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its
charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] |
No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________
Company Announcement
12 August 2010
Novo Nordisk A/S – Share repurchase programme
As part of the execution of Novo Nordisk A /S’ DKK 8.5 billion share repurchase programme for 2010, a share repurchase programme has been initiated in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
For that purpose Novo Nordisk A/S has appointed J. P. Morgan Securities Ltd. as lead manager to independently and without influence from Novo Nordisk execute the programme. The purpose of the programme is reduction of the company’s share capital. Under the agreement J. P. Morgan Securities Ltd. will repurchase shares on behalf of Novo Nordisk A/S for an amount of up to DKK 1.0 billion during the trading period starting 12 August 2010 and ending on 25 October 2010. A maximum of 119,587 shares can be bought during one single trading day, equal to 20% of the average daily trading volume of Novo Nordisk B shares on NASDAQ OMX Copenhagen during the month of July 2010, and a maximum of 6,338,111 shares in total can be bought during the trading period. At least once every seven trading days, Novo Nordisk will issue an announcement in respect of the transactions made under the repurchase programme.
Company Announcement no 46 / 2010 |
Page 1 of 2 |
|||
|
||||
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 6626 |
Internet: novonordisk.com |
CVR no: 24256790 |
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Further information: |
|
|
|
Media: |
Investors: |
|
|
Outside North America: Anne Margrethe Hauge Tel: (+45) 4442 3450 amhg@novonordisk.com |
Outside North America: Klaus Bülow Davidsen Tel: (+45) 4442 3176 klda@novonordisk.com |
|
|
|
Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com |
|
|
In North America: Sean Clements Tel: (+1) 609 514 8316 secl@novonordisk.com |
In North America: Hans Rommer Tel: (+1) 609 919 7937 hrmm@novonordisk.com |
Company Announcement no 46 / 2010 |
Page 2 of 2 |
|||
|
||||
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 6626 |
Internet: novonordisk.com |
CVR no: 24256790 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: AUGUST 13, 2010 |
NOVO NORDISK A/S Lars Rebien Sørensen, President and Chief Executive Officer |